Cartesian Therapeutics (RNAC) Revenue (2016 - 2025)
Historic Revenue for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $452000.0.
- Cartesian Therapeutics' Revenue rose 1679.59% to $452000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 9772.41%. This contributed to the annual value of $38.9 million for FY2024, which is 4964.24% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Revenue is $452000.0, which was up 1679.59% from $298000.0 recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Revenue ranged from a high of $39.3 million in Q2 2022 and a low of -$759000.0 during Q4 2024
- Moreover, its 5-year median value for Revenue was $8.3 million (2023), whereas its average is $13.8 million.
- Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Revenue was 53716.9% (2024), while the steepest drop was 10918.22% (2024).
- Quarter analysis of 5 years shows Cartesian Therapeutics' Revenue stood at $29.9 million in 2021, then crashed by 43.9% to $16.8 million in 2022, then crashed by 50.78% to $8.3 million in 2023, then plummeted by 109.18% to -$759000.0 in 2024, then skyrocketed by 159.55% to $452000.0 in 2025.
- Its last three reported values are $452000.0 in Q3 2025, $298000.0 for Q2 2025, and $1.1 million during Q1 2025.